This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alastair Compston, MBBS, FRCP, PhD

Arch Neurol. 1988;45(6):669-670.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The application of imaging methods in assessing disease activity in patients with multiple sclerosis (MS) is beginning to influence strategies for treatment. Meanwhile, most clinicians treat patients with severe disability symptomatically, reserving experimental therapies aimed at modifying the long-term course for those in whom disability is accumulating and leaving mild cases untreated. Although corticosteroids have an established role in the treatment of MS in relapse, it is not clear how the balance between beneficial and adverse effects can best be achieved. Enthusiasts now claim that high-dose intravenously administered methylprednisolone is more effective, less complicated, benefits a wider range of patients, and has more than just an anti-inflammatory effect on the disease process; many clinicians are now switching to this regimen as the preferred means of administering corticosteroids to patients with MS.

Following the initial report of clinical improvement in five of seven patients with acute demyelination,¹ open comparisons showed . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, University of Wales College of Medicine, Cardiff.

Footnotes
Accepted for publication Jan 25, 1988.

Reprint requests to Department of Medicine, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, Wales (Dr Compston).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?